A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
← catalyst calendarNCT07144280 · readout in 569 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
680estimated
Sites
425
Countries
Argentina, Australia, Belgium +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-29 | actual | When the study began enrolling |
| Primary completion | 2028-03-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-03-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-small Cell Carcinoma
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Carcinoma
Interventions
- Drug: PF-08046054 — also filed as SGN-PDL1V
- Drug: Docetaxel monotherapy
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Approximately 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed